Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
5α-reductase type 1 is an isoenzyme of the steroid 5α-reductase family, which catalyzes the conversion of testosterone to dihydrotestosterone (DHT). It is encoded by the SRD5A1 gene and is highly expressed in liver and skin. DHT produced by this enzyme is essential for male sexual differentiation and development. Overexpression is observed during prostate cancer progression. It is targeted by 5α-reductase inhibitors like finasteride, used for benign prostatic hyperplasia and androgenic alopecia.
5α-reductase inhibitor
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Steroid 5α-reductase type I.